Market Research Logo

Global Lifestyle Drugs Market 2017-2021

Global Lifestyle Drugs Market 2017-2021

About Lifestyle Drugs Market

Lifestyle disease is associated with the way an individual or group of people live. Some of the lifestyle diseases include depression, sexual dysfunction, anti-aging, baldness, and obesity.

Technavio’s analysts forecast the global lifestyle drugs market to grow at a CAGR of 2.87% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global lifestyle drugs market for 2017-2021. To calculate the market size, the report considers sales of lifestyle drugs in the market.

The market is divided into the following segments based on geography:

  • Americas
  • EMEA
  • APAC
Technavio's report, Global Lifestyle Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

key vendors
  • Allergan
  • BMS
  • Eli Lilly
  • Pfizer
Other prominent vendors
  • Acerus Pharmaceuticals
  • Alkermes
  • Amorepacific
  • AndroScience
  • Anterios
  • AstraZeneca
  • Avanir Pharmaceuticals
  • Avolynt
  • Celtaxsys
  • Cerecor
  • Corcept Therapeutics
  • Cosmo Pharmaceuticals
  • CTC Bio
  • Dermira
  • Dong-A ST
  • Euthymics Bioscience
  • Foamix
  • Follicum
  • Forendo Pharma
  • Futura Medical Developments
  • Galderma
  • Hanmi Pharmaceutical
  • Incyte
  • Intrepid Therapeutics
  • Ion Channel Innovations
  • iX Biopharma
  • Johnson & Johnson
  • Legacy Healthcare
  • LEO Pharma
  • H. Lundbeck
  • Luye America Pharmaceuticals
  • Merck
  • Minerva Neurosciences
  • MSI Methylation Sciences
  • Neuralstem
  • Novan
  • Novartis
  • Novo-Nordisk
  • Palatin Technologies
  • Paratek Pharmaceuticals
  • Photocure
  • Revance Therapeutics
  • Rhythm Pharmaceuticals
  • S1 Biopharma
  • Sage Therapeutics
  • Samumed
  • Sanofi
  • Sigma-Tau Pharmaceuticals
  • Strategic Science & Technologies
  • Sumitomo Dainippon Pharma
  • Takeda
  • TetraLogic Pharmaceuticals
  • TherapeuticsMD
  • Valeant Pharmaceuticals
  • VistaGen Therapeutics
  • VIVUS
  • XBiotech
  • Yuhan
  • Zafgen
Market driver
  • Lifestyle changes
  • For a full, detailed list, view our report
Market challenge
  • Patent expiries
  • For a full, detailed list, view our report
Market trend
  • Increase in M&A
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


  • Executive summary
  • Scope of the report
  • Research Methodology
  • Introduction
    • Key market highlights
  • An overview of lifestyle diseases
  • Market landscape
    • Market overview
      • Table Global lifestyle drugs market snapshot
      • Table Global lifestyle drugs market 2016-2021 ($ billions)
      • Table Opportunity analysis in global lifestyle drugs market
    • Five forces analysis
      • Table Five forces analysis
  • Pipeline landscape
    • Table Pipeline analysis of vendors in Phase III
    • Table Key pipeline drugs for depression 2016
    • Table Key pipeline drugs for dermatology (anti-aging, baldness, and acne) 2016
    • Table Key pipeline drugs for sexual dysfunction 2016
    • Table Key pipeline drugs for obesity
  • Market segmentation by therapy area
    • Depression
      • Table Global depression drugs market 2016-2021 ($ billions)
    • Dermatology (acne, anti-aging, and baldness)
      • Table Global dermatology lifestyle drugs market 2016-2021 ($ billions)
    • Sexual dysfunction
      • Table Global sexual dysfunction drugs market 2016-2021 ($ billions)
    • Obesity
      • Table Global obesity drugs market 2016-2021 ($ billions)
  • Geographical segmentation
    • Table Segmentation of global lifestyle drugs market by geography 2016 and 2021
    • Table Global lifestyle drugs market revenue by geography 2016-2021 ($ billions)
    • Lifestyle drugs market in Americas
      • Table Market scenario in Americas
      • Table Lifestyle drugs market in Americas 2016-2021 ($ billions)
    • Lifestyle drugs market in EMEA
      • Table Market scenario in EMEA
      • Table Lifestyle drugs market in EMEA 2016-2021 ($ billions)
    • Lifestyle drugs market in APAC
      • Table Market scenario in APAC
      • Table Lifestyle drugs market in APAC 2016-2021 ($ billions)
  • Market drivers
    • Lifestyle changes
    • Development of novel therapeutics
    • Increasing demand from older population
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Patent expiries
    • Side effects coupled with product recalls
    • Presence of alternative therapies and treatments
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Increase in M&A
    • Growing focus on development of drugs for new indications
    • Emerging lifestyle diseases
  • Vendor landscape
    • Competitive scenario
      • Table Competitive structure analysis of global lifestyle drugs market 2016
      • Table Competitive analysis of global lifestyle drugs market
      • Table Market penetration of various lifestyle drug manufacturers worldwide 2016
      • Table Strategic success factors of companies in global lifestyle drugs market
  • Key vendor analysis
    • Allergan
      • Table Allergan: Key highlights
      • Table Allergan: Strength assessment
      • Table Allergan: Strategy assessment
      • Table Allergan: Opportunity assessment
    • BMS
      • Table BMS: Strength assessment
      • Table BMS: Strategy assessment
      • Table BMS: Opportunity assessment
      • Table BMS: YoY and growth rate of Abilify 2013-2015 ($ billions)
    • Eli Lilly
      • Table Eli Lilly: Key highlights
      • Table Eli Lilly: Strength assessment
      • Table Eli Lilly: Strategy assessment
      • Table Eli Lilly: Opportunity assessment
      • Table Eli Lilly: YoY and growth rate of Cymbalta 2013-2015 ($ millions)
      • Table Eli Lilly: YoY and growth rate of Zyprexa 2013-2015 ($ millions)
      • Table Eli Lilly: YoY and growth rate of Strattera 2013-2015 ($ millions)
      • Table Eli Lilly: YoY and growth rate of Cialis 2013-2015 ($ millions)
    • Pfizer
      • Table Pfizer: Key highlights
      • Table Pfizer: Strength assessment
      • Table Pfizer: Strategy assessment
      • Table Pfizer: Opportunity assessment
      • Table Pfizer: YoY and growth rate of Pristiq 2013-2015 ($ millions)
      • Table Pfizer: YoY and growth rate of Zoloft 2013-2015 ($ millions)
      • Table Pfizer: YoY and growth rate of Effexor 2013-2015 ($ millions)
      • Table Pfizer: YoY and growth rate of Viagra 2013-2015 ($ millions)
    • Other prominent vendors
  • Appendix
    • List of abbreviation
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report